Earnings up, book down 15% — the payout outruns EAD. A quarterly payer at $0.51 a share, $2.04 annualized, held flat — and third-quarter earnings available for distribution of $0.38 a share covered only 74% of that dividend, even as EAD rose from $0.36 in the second quarter on higher net interest income of $101.6 million. The quarter behind it is the problem: book value fell 15.4% in three months to $10.91, from $12.90 at June 30, as wider Agency MBS spreads overwhelmed hedge gains, for a negative 11.5% economic return and a $1.49 per share comprehensive loss. Leverage rose to 9.0× equity, up from 8.1×, largely because the book shrank underneath it, though liquidity of $1.3 billion — over 42% of equity — stayed substantial. EAD is real income, not returned capital, which is what keeps this a warning rather than a trap — but a dividend at 134% of EAD on a book that just lost 15% is a warning with a short fuse.
Key risk: Rates and spreads — Agency MBS marks at 9.0× leverage. Further spread widening hits book value again and pushes leverage higher without any new borrowing; if EAD slips back toward $0.36, the $0.51 rate has even less cover.
Changes if: EAD falls back below $0.38, book value falls for a second straight quarter, or leverage rises past 9.0×. Any of those turns an uncovered quarter into a cut question.
- ✗Earnings coverage check: Third-quarter EAD of $0.38 a share covered 74% of the $0.51 dividend — improved from $0.36 in the second quarter, but still a quarter of the payout beyond what the portfolio earned.
- ✗Book-value check: Book value fell 15.4% in the third quarter alone to $10.91, from $12.90 at June 30, for a negative 11.5% economic return after the $0.51 dividend — spread widening, not earnings, drove the quarter.
- !Leverage check: Leverage of 9.0× equity, up from 8.1×, rose mostly because book value fell — the structure amplifies every spread move, though $1.3 billion of liquidity leaves room to hold positions rather than sell into weakness.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.